Self-Assembling Therapeutics for Specific Nanoscale Interactions with the Sodium Pump

该项目的长期科学目标是准备新的有效疗法，为此，我们需要确保我们的新设备达到它们的生物目标，并在特定疾病应用中被证明有效，然后我们才能开始一个更大的计划，以指导它们向临床实践的发展。欧洲科学基金会(ESF)纳米医学展望描述了用于靶向药物输送的新的多功能、空间有序、结构变化的系统的开发是优先的。基于抗体-药物结合物和聚合物-生物聚合物结合物的纳米药物是增强疗效药物的关键组成部分。虽然更复杂，但这些结合物提供了增强的多样性，导致与小分子化合物相比，药物的信息含量要高得多。这允许更大的靶标特异性、改进的功能和多任务的机会，例如就地诊断和治疗，或同时作用于一个以上的治疗靶点或疾病途径。因此，我们将在本计划中准备的新型共轭纳米设备是唯一能够解决目前未得到充分治疗的疾病的设备。通过开发新的生物靶点和界面，我们的材料将在改善疾病引起的患者、经济和社会结果方面迈出重要的一步。

The long-term science for this project is directed towards the preparation of new and effective therapeutics, and to dothis we need to ensure that our novel devices hit their biological targets and have proven efficacyin a particular disease application before we can commence a larger programme to guide theirdevelopment towards clinical practice. The European Science Foundation (ESF) Nanomedicine Forward Look describes the development ofnew multifunctional, spatially ordered, architecturally-varied systems for targeted drug delivery as apriority. Nanopharmaceuticals based on antibody-drug conjugates and polymer-biopolymerconjugates are a key component of enhanced efficacy medicines. While more complex, theseconjugates offer enhanced diversity, leading to drugs with much higher information content comparedto small molecule compounds. This allows for greater target specificity, improved functionality andthe opportunity to multi-task, for example to diagnose and treat in situ, or to act on more than onetherapeutic target or disease pathway simultaneously. The novel conjugate nanodevices we willprepare in this programme are thus uniquely able to address diseases which are inadequately treatednow. By exploiting new biological targets and interfaces, our materials will contribute a vital step inimproving patient, economic and society outcomes arising from disease.